Park Edge Advisors LLC Sells 805 Shares of Pfizer Inc. (NYSE:PFE)

Park Edge Advisors LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,433 shares of the biopharmaceutical company’s stock after selling 805 shares during the quarter. Park Edge Advisors LLC’s holdings in Pfizer were worth $675,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC grew its stake in Pfizer by 1.6% during the second quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock worth $17,068,000 after buying an additional 9,435 shares during the last quarter. Raab & Moskowitz Asset Management LLC grew its position in Pfizer by 52.7% during the 2nd quarter. Raab & Moskowitz Asset Management LLC now owns 238,937 shares of the biopharmaceutical company’s stock worth $6,685,000 after acquiring an additional 82,497 shares during the last quarter. MidWestOne Financial Group Inc. increased its holdings in Pfizer by 1.5% during the 2nd quarter. MidWestOne Financial Group Inc. now owns 26,530 shares of the biopharmaceutical company’s stock valued at $742,000 after purchasing an additional 386 shares in the last quarter. Straight Path Wealth Management raised its position in Pfizer by 21.3% in the 2nd quarter. Straight Path Wealth Management now owns 37,025 shares of the biopharmaceutical company’s stock valued at $1,036,000 after purchasing an additional 6,513 shares during the last quarter. Finally, Ascent Group LLC boosted its stake in Pfizer by 23.2% in the second quarter. Ascent Group LLC now owns 50,845 shares of the biopharmaceutical company’s stock worth $1,423,000 after purchasing an additional 9,565 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

Pfizer Trading Down 1.3 %

NYSE:PFE opened at $26.10 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market capitalization of $147.89 billion, a price-to-earnings ratio of 35.27, a PEG ratio of 0.64 and a beta of 0.64. The business’s 50-day moving average price is $26.11 and its two-hundred day moving average price is $27.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the company posted ($0.17) EPS. On average, equities analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.59%. Pfizer’s payout ratio is 227.03%.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Bank of America reiterated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.